Lead Screenings (Medicaid and CHIP)
Lead exposure, especially among young children, continues to be a significant part of the national discussion regarding health issues. According to the Centers for Disease Control (CDC), even low levels of lead in blood have been shown to affect a child’s IQ, their ability to pay attention, and academic achievement. As recently as 2012, children with a blood lead level of 10 micrograms per deciliter of blood (μg/dL) or greater were considered to be a concern. However, the CDC’s current guidelines now reference a blood level of only 5 micrograms per deciliter to identify children with elevated blood levels.
Lead testing is especially vital in Philadelphia County, which is designated as a “high blood lead area.” For patients in Philadelphia County with an abnormal blood lead level, refer them for an Environmental Lead Investigation (ELI) by completing and faxing a form to the City of Philadelphia.
Lead Testing Kit Recall
Magellan Diagnostics, Inc. has expanded their product recall involving the LeadCare® blood test kits to include all its LeadCare II Blood Lead Test Kits, LeadCare Plus Blood Lead Test Kits, and LeadCare Ultra Blood Lead Test Kits because they could potentially underestimate blood lead levels when processing patient blood samples. Magellan Diagnostics has temporarily stopped shipments of LeadCare® test kits and has not issued a definitive date to resume shipments.
- Providers and healthcare organizations should discontinue the use of all LeadCare® II testing supply kits and quarantine the remaining inventory.
- Providers and healthcare organizations should identify and contact patients tested with recalled test kit lots. All results tested on impacted lots should be confirmed with an alternative lead testing option analyzed using a high complexity testing method, such as Inductively Coupled Plasma Mass Spectrometry (ICP-MS) or Graphite Furnace Atomic Absorption Spectroscopy (GFAAS) at a high complexity, CLIA-certified, reference laboratory.
- Please call DOH at 1-877-PA-HEALTH or your local health department if you have any questions.
- Review the Health Advisory from DHS.
All Health Partners (Medicaid) and KidzPartners (CHIP) members are required to have a lead test completed before 12 months and at 24 months. Current CHIP policy requires that all children ages one and two years old and all children ages three through six without a prior lead blood test have blood levels screened consistent with current Department of Health and CDC standards.
In the event that testing is not completed during these timeframes, we urge your office to perform testing at the next well-child visit.
Testing can be conducted in either your office or at a Quest Diagnostics Drawing Station. When you conduct an ‘In-Office Lab Draw’ lead screening test, please note that you should submit CPT code 83655. If the testing occurs at a Quest Diagnostics Drawing Station, be sure to provide a prescription to the parent/guardian to enable them to visit any Quest Diagnostics location. Find the closest testing facility by utilizing the Provider Directory and searching for “Quest Diagnostics.”
Medical treatment is not recommended for children with blood lead levels lower than 45 micrograms per deciliter, according to CDC recommendations. However, parents should learn about possible sources of lead exposure and attempt to determine if one or more sources of lead are present in their home. Parents then can follow the CDC’s recommendations to control children’s exposure to lead.
- Children can be given a blood test to measure the level of lead in their blood. These tests are covered by Medicaid and most private health insurance.
- Chelation therapy should be considered for any child that has a blood lead test result greater than or equal to 45 micrograms per deciliter.
Recommended Schedule for Obtaining a Confirmatory Venous Sample
Blood Lead Level (μg/dL)
Time to Confirmation Testing
|10-44||1 week-1 month*|
|≥70||Urgently as emergency test|
* The higher the BLL on the screening test, the more urgent the need for confirmatory testing.
Recommended Schedule for Follow-Up Blood Lead Testing
Venous Blood Lead Levels (µg/dL)
Early Follow Up Testing (2-4 tests after Identification)
Later Follow Up Testing after BLL Declining
|≥5–9||3 months*||6-9 months|
|10-19||1-3 months*||3-6 months|
|20-24||1-3 months*||1-3 months|
|25-44||2 weeks - 1 month||1 month|
|≥45||As soon as possible||As soon as possible|
* Seasonal variation of BLLs exists and may be more apparent in colder climate areas. Greater exposure in the summer months may necessitate more frequent follow ups.
Some case managers or health care providers may choose to repeat blood lead tests on all new patients within a month to ensure that their BLL level is not rising more quickly than anticipated.
Environmental Lead Investigation (ELI) Form
An ELI form is required for Health Partners members under the age of 21 with a blood lead screening result of at least 5 μg/dL, and where there are environmental influences for lead contamination. The order for an ELI must include a primary diagnosis code of toxic effect of lead and its components. It is free for Health Partners members.
HPP encourages providers to check these online resources for more information about preventing lead exposure and removing lead paint from PA homes.
Please contact county-based health departments and programs that offer resources, screening guidelines and other information.